COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma

Alexander C.J. Van Akkooi; Axel Hauschild; Georgina V. Long; Mario Mandala; Michal Kicinski; Anne Sophie Govaerts; Isabelle Klauck; Monia Ouali; Paul C. Lorigan; Alexander M.M. Eggermont

doi:10.2217/fon-2023-0414

COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma

Alexander C.J. Van Akkooi
, Axel Hauschild
, Georgina V. Long
, Mario Mandala
, Michal Kicinski
, Anne Sophie Govaerts
, Isabelle Klauck
, Monia Ouali
, Paul C. Lorigan
, Alexander M.M. Eggermont^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

4 Downloads (Pure)

Abstract

Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.

Original language	English
Pages (from-to)	2017-2027
Number of pages	11
Journal	Future Oncology
Volume	19
Issue number	30
DOIs	https://doi.org/10.2217/fon-2023-0414
Publication status	Published - 1 Sept 2023

Keywords

binimetinib
BRAF inhibitor
clinical trial
encorafenib
MEK inhibitor
melanoma
stage IIB
stage IIC

Access to Document

10.2217/fon-2023-0414Licence: CC BY-NC-ND

COLUMBUS-AD Phase III Study of Adjuvant Encorafenib Binimetinib in Resected Stage IIB IIC BRAF V600-Mutated MelanomaFinal published version, 1.83 MBLicence: CC BY-NC-ND

Cite this

@article{b7dfc4d230e049b4b52454bd7a1914c5,

title = "COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma",

abstract = "Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.",

keywords = "binimetinib, BRAF inhibitor, clinical trial, encorafenib, MEK inhibitor, melanoma, stage IIB, stage IIC",

author = "\{Van Akkooi\}, \{Alexander C.J.\} and Axel Hauschild and Long, \{Georgina V.\} and Mario Mandala and Michal Kicinski and Govaerts, \{Anne Sophie\} and Isabelle Klauck and Monia Ouali and Lorigan, \{Paul C.\} and Eggermont, \{Alexander M.M.\}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

month = sep,

day = "1",

doi = "10.2217/fon-2023-0414",

language = "English",

volume = "19",

pages = "2017--2027",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "30",

}

TY - JOUR

T1 - COLUMBUS-AD

T2 - phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma

AU - Van Akkooi, Alexander C.J.

AU - Hauschild, Axel

AU - Long, Georgina V.

AU - Mandala, Mario

AU - Kicinski, Michal

AU - Govaerts, Anne Sophie

AU - Klauck, Isabelle

AU - Ouali, Monia

AU - Lorigan, Paul C.

AU - Eggermont, Alexander M.M.

PY - 2023/9/1

Y1 - 2023/9/1

N2 - Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.

AB - Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.

KW - binimetinib

KW - BRAF inhibitor

KW - clinical trial

KW - encorafenib

KW - MEK inhibitor

KW - melanoma

KW - stage IIB

KW - stage IIC

UR - https://www.scopus.com/pages/publications/85174752310

U2 - 10.2217/fon-2023-0414

DO - 10.2217/fon-2023-0414

M3 - Review article

C2 - 37665297

AN - SCOPUS:85174752310

SN - 1479-6694

VL - 19

SP - 2017

EP - 2027

JO - Future Oncology

JF - Future Oncology

IS - 30

ER -

COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this